荣昌生物(09995.HK)偶联药维迪西妥单抗Ⅲ期临床研究达主要研究终点

阿斯达克财经
12 May

荣昌生物(09995.HK) 公布,公司自主研发的抗体偶联药物(ADC)维迪西妥单抗联合特瑞普利单抗对比化疗治疗HER2表达的一线局部晚期或转移性尿路上皮癌的Ⅲ期临床研究达到无进展生存期和总生存期两项主要研究终点。公司将择机向国家药品监督管理局药品审评中心递交该适应症的新药上市申请。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-12 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10